Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Johnson & Johnson

- PMLiVE

J&J’s subcutaneous Tremfya shows promise in phase 3 Crohn’s disease study

Inflammatory bowel disease affects approximately four million people in Europe

- PMLiVE

Johnson & Johnson’s investigational nipocalimab shows promise in Sjögren’s disease

The chronic autoimmune disease is estimated to affect four million people worldwide

- PMLiVE

AbbVie gains rights to FutureGen’s inflammatory bowel disease candidate in deal worth $1.7bn

The agreement gives AbbVie exclusive global rights to the TL1A-targeting monoclonal antibody

- PMLiVE

J&J agrees $700m settlement with US states to resolve talcum powder claims

The company has ended global sales of the affected products in favour of cornstarch versions

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn

The company will expand its immunology portfolio by gaining global rights to YJT’s NM26 in atopic dermatitis

- PMLiVE

New study aims to identify IBD biomarkers for personalised medicine

The chronic gastrointestinal condition affects more than 540,000 people in the UK

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

J&J’s Rybrevant combination recommended by CHMP to treat advanced lung cancer

The fully-human EGFR-MET bispecific antibody has been recommended as a first-line treatment option

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links